Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery

Pharm Res. 2007 Aug;24(8):1405-14. doi: 10.1007/s11095-007-9284-6. Epub 2007 Mar 29.

Abstract

The success of anti-cancer therapies largely depends on the ability of the therapeutics to reach their designated cellular and intracellular target sites, while minimizing accumulation and action at non-specific sites. Surface modification of nanoparticulate carriers with poly(ethylene glycol) (PEG)/poly(ethylene oxide) (PEO) has emerged as a strategy to enhance solubility of hydrophobic drugs, prolong circulation time, minimize non-specific uptake, and allow for specific tumor-targeting through the enhanced permeability and retention effect. Furthermore, PEG/PEO modification has emerged as a platform for incorporation of active targeting ligands, thereby providing the drug and gene carriers with specific tumor-targeting properties through a flexible tether. This review focuses on the recent developments surrounding such PEG/PEO-surface modification of polymeric nanocarriers to promote tumor-targeting capabilities, thereby enhancing efficacy of anti-cancer therapeutic strategies.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Drug Delivery Systems / methods*
  • Genetic Therapy / methods*
  • Humans
  • Models, Biological
  • Nanoparticles / chemistry*
  • Neoplasms / drug therapy
  • Neoplasms / therapy*
  • Polyethylene Glycols / chemistry*

Substances

  • Antineoplastic Agents
  • Polyethylene Glycols